Search company, investor...

Novazyme Pharmaceuticals

genzymepharmaceuticals.com

Founded Year

1999

Stage

Acquired | Acquired

Total Raised

$24M

Valuation

$0000 

About Novazyme Pharmaceuticals

Novazyme was an early stage Pharmaceutical company developing biotherapies for the treatment of lysosomal storage disorders.

Headquarters Location

353 Nassau Street Suite 200

Princeton, New Jersey, 08540,

United States

609-683-4400

Missing: Novazyme Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Novazyme Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Novazyme Pharmaceuticals News

A look back can show the way forward for Oklahoma innovation

Apr 25, 2018

By Scott Meacham Copyright © 2018, The Oklahoma Publishing Co. If you are a regular reader of these columns, and I hope you are, you can tell that I like history. There are the lessons, of course, and the perspective we gain from looking back. And there are the celebratory moments. There’s always an “aha” moment in history, although we may not recognize it at the time. This year, as i2E is celebrating our 20th anniversary, I got to thinking about what we’ll be remembered for another 20 years from now. Over 20 years, it is easy to misplace the details of some of our state’s greatest stories. Take Novazyme Pharmaceuticals, founded by William Canfield, MD, PhD, formerly a scientist at the University of Oklahoma Health Sciences Center and taken through a much-heralded exit by CEO John Crowley. Canfield’s research made a breakthrough in the treatment of a rare genetic disorder called Pompe disease. It’s a form a muscular dystrophy that happens at birth and later in life and causes muscle weakness that typically leads to death, especially in children. Crowley, an experienced drug industry executive and the father of two children suffering from Pompe disease, came into Novazyme as CEO to hasten the progress of an FDA-approved drug. Genzyme acquired Novazyme and eventually achieved FDA-approval for the drug that Crowley credits with saving his children’s lives. The story of Novazyme and Crowley’s determination to develop a drug that would help his children has been told in books, adapted for Hollywood in the movie “Extraordinary Measures,” and highlighted in the 2017 State of the Union address. What doesn’t always get told as fully is the Oklahoma back story. Years of research and experimentation led up to Canfield’s discovery. Novazyme began in subsidized state-of-the-art lab space in the research park. And the first investor in Novazyme was i2E through the Technology Business Finance Program (TBFP) Concept Fund. Nearly 20 years ago, when, at the behest of the Oklahoma Center for the Advancement of Science and Technology and the organization that was to become i2E, the Oklahoma legislature boldly gave the TBFP concept fund the green light, there was hope and belief that the concept fund would stand the test of time and become evergreen — and it has. Genzyme created a second drug that is used to treat all patients who suffer from Pompe disease. Canfield has started more companies; Crowley is a serial CEO of biotech firms, and the TBFP Concept Fund, which has been self-sustaining since 2011, has invested in 122 companies. That’s the kind of impact that innovation leaders had in mind in the late nineties when they pressed the Oklahoma Legislature to authorize state appropriations for a concept fund. To that, I say, “aha!” Scott Meacham is president and CEO of i2E Inc., a nonprofit corporation that mentors many of the state’s technology-based startup companies. i2E receives state support from the Oklahoma Center for the Advancement of Science and Technology and is an integral part of Oklahoma’s Innovation Model. Contact Meacham at i2E_Comments@i2E.org .

Novazyme Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Novazyme Pharmaceuticals founded?

    Novazyme Pharmaceuticals was founded in 1999.

  • Where is Novazyme Pharmaceuticals's headquarters?

    Novazyme Pharmaceuticals's headquarters is located at 353 Nassau Street, Princeton.

  • What is Novazyme Pharmaceuticals's latest funding round?

    Novazyme Pharmaceuticals's latest funding round is Acquired.

  • How much did Novazyme Pharmaceuticals raise?

    Novazyme Pharmaceuticals raised a total of $24M.

  • Who are the investors of Novazyme Pharmaceuticals?

    Investors of Novazyme Pharmaceuticals include Genzyme, Aisling Capital, Catalyst Health Ventures, Perseus and Metalmark Capital.

  • Who are Novazyme Pharmaceuticals's competitors?

    Competitors of Novazyme Pharmaceuticals include Neurelis, Ology Bioservices, Neuraltus Pharmaceuticals, Pozen, Collegium Pharmaceutical and 12 more.

Compare Novazyme Pharmaceuticals to Competitors

Aestus Therapeutics Logo
Aestus Therapeutics

Aestus Therapeutics, Inc. is a translational medicine company focused on the treatment of disorders of the nervous system. Aestus's core technology aims to utilize a process for mining both public gene expressions and pharmaceutical data (the Aestus engine).

Neurelis Logo
Neurelis

Neurelis is a specialty pharmaceutical company that devleops and commercializes product candidates for epilepsy and the broader central nervous system (CNS) market.

I
Intranasal Therapeutics

Intranasal Therapeutics, founded in 1998 by Edwin Cohen, founder and former Chairman and CEO of Barr Laboratories, Intranasal Therapeutics, Inc. (ITI) is a specialty pharmaceutical company focused on developing nasally delivered pharmaceutical products, with a particular focus on drugs treating pain and disorders related to the central nervous system.

I
Ikano Therapeutics

Ikano Therapeutics is a specialty pharmaceutical company focused on developing nasally delivered pharmaceutical products with a particular focus on drugs treating pain and disorders related to the central nervous system.

S
Slate Pharmaceuticals

Slate currently markets Testopel in the United States. Testopel is an FDA-approved subcutaneous implantable testosterone pellet. Testopel is used for the treatment of testosterone deficiency in aging men as well as androgen deficiency caused by other conditions.

P
Pradama

Pradama, Inc. is a pharmaceutical company focused on the development and commercialization of products to treat bone diseases and disorders. Pradama is developing compounds that target bone with the initial two products designed for osteoporosis treatment and an antineoplastic compound for the treatment of bone metastases.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.